|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Clevidipine#Pharmacology]] |
| {{Clevidipine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Description==
| |
| | |
| Cleviprex is a sterile, milky-white emulsion containing 0.5 mg/mL of clevidipine suitable for intravenous administration. Clevidipine is a dihydropyridine calcium channel blocker. Chemically, the active substance, clevidipine, is butyroxymethyl methyl 4-(2´,3´-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate. It is a racemic mixture with a molecular weight of 456.3 g/mol. Each enantiomer has equipotent antihypertensive activity. The structure and formula are:
| |
| {|
| |
| |[[File:clevidipine03.jpg|thumb|800px]]
| |
| |}
| |
| | |
| {|
| |
| |[[File:clevidipine04.jpg|thumb|800px]]
| |
| |}
| |
| | |
| Clevidipine is practically insoluble in water and is formulated in an oil-in-water emulsion. In addition to the active ingredient, clevidipine, Cleviprex contains soybean oil (200 mg/mL), glycerin (22.5 mg/mL), purified egg yolk phospholipids (12 mg/mL), oleic acid (0.3 mg/mL), disodium edetate (0.05 mg/mL), and sodium hydroxide to adjust pH. Cleviprex has a pH of 6.0 – 8.0 and is a ready-to-use emulsion. | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CLEVIPREX (CLEVIDIPINE) EMULSION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=095081a0-1398-11dc-82e1-0002a5d5c51b | publisher = | date = | accessdate = 27 February 2014 }}</ref>
| |
| | |
| ==References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Calcium channel blockers}}
| |
| | |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Dihydropyridines]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Butyrates]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |